Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 8

Results For "NCEs"

2684 News Found

Gilead Sciences breaks ground on new manufacturing and technical development site in US
News | September 09, 2025

Gilead Sciences breaks ground on new manufacturing and technical development site in US

New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value


Zydus Lifesciences appoints Nitin Parekh as President (Special Projects)
People | September 08, 2025

Zydus Lifesciences appoints Nitin Parekh as President (Special Projects)

He has been associated with the Zydus Group since 2009


Zydus Lifesciences gets 4 USFDA observations for Jarod Injectable facility
News | September 06, 2025

Zydus Lifesciences gets 4 USFDA observations for Jarod Injectable facility

Zydus will work closely with the USFDA to address and resolve the observations in an expeditious manner


Edwards Lifesciences launches next-gen transcatheter heart valve in India
News | September 05, 2025

Edwards Lifesciences launches next-gen transcatheter heart valve in India

Edwards’ latest-generation balloon-expandable transcatheter heart valve incorporates a proprietary calcification-resistant tissue technology


Quotient Sciences and CPI join forces to accelerate RNA drug development
News | September 05, 2025

Quotient Sciences and CPI join forces to accelerate RNA drug development

The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products


Sai Life Sciences completes Phase II of production block 11 at Bidar
News | August 29, 2025

Sai Life Sciences completes Phase II of production block 11 at Bidar

With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL


AbbVie announces positive topline results from second Phase 3 UP-AA trial evaluating Upadacitinib
News | August 23, 2025

AbbVie announces positive topline results from second Phase 3 UP-AA trial evaluating Upadacitinib

The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study


Sarepta advances siRNA collaboration and sale of arrowhead equity investment
News | August 19, 2025

Sarepta advances siRNA collaboration and sale of arrowhead equity investment

Sarepta has also entered into an agreement with Arrowhead to transfer 2,660,989 shares of Arrowhead common stock in satisfaction of $50 million of the company’s previously announced $100 million milestone payment obligation